Logo

Protein Forest Closes $19M Series A

Nov 21, 2003

NEW YORK, Nov. 21 (GenomeWeb News) - Proteomics separations start-up ProteinForest announced today that it has closed a $19 million Series A financing.

 

The Watertown, Mass.-based company's technology consists of a suite of products centered around the ProteomeChip - developed by three Israeli physicists - which the company claims can separate and image all proteins in a biological sample in one hour or less, with high sensitivity, reproducibility, and accuracy. The company is currently led by CEO Russell Garlick, former vice president of R&D at PerkinElmer.

 

S.R. One, Boston Millennia Partners, IDG Venture, and Novo A/S led the Series A financing.

 

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.